World Investment Advisors Sells 7,271 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

World Investment Advisors trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 66.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,716 shares of the biotechnology company’s stock after selling 7,271 shares during the quarter. World Investment Advisors’ holdings in Arrowhead Pharmaceuticals were worth $233,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ARWR. CWM LLC increased its position in Arrowhead Pharmaceuticals by 1.4% during the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock worth $820,000 after acquiring an additional 168 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 1.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares during the period. HighTower Advisors LLC raised its position in shares of Arrowhead Pharmaceuticals by 0.3% in the fourth quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock valued at $8,845,000 after buying an additional 340 shares in the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Arrowhead Pharmaceuticals by 1.8% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,241 shares of the biotechnology company’s stock valued at $1,344,000 after buying an additional 365 shares during the period. Finally, Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $74.11 on Tuesday. The business has a fifty day simple moving average of $77.92 and a 200 day simple moving average of $69.42. The company has a market cap of $10.44 billion, a P/E ratio of -34.47 and a beta of 1.26. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $14.30 and a twelve month high of $87.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same quarter in the previous year, the firm earned $2.75 earnings per share. The business’s quarterly revenue was down 86.4% on a year-over-year basis. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on ARWR. JPMorgan Chase & Co. initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective on the stock. Chardan Capital reiterated a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 30th. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Sanford C. Bernstein raised their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $87.27.

Insider Buying and Selling

In related news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This represents a 5.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the transaction, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. The trade was a 7.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 26,065 shares of company stock worth $1,912,662 in the last three months. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.